Sustainability is becoming an increasingly important consideration across the pharmaceutical value chain — including the manufacturing of therapeutic oligonucleotides.
In a recent publication in Chemistry Today – Chimica Oggi, BioSpring’s Head of Corporate Development, Governance & Sustainability, Dr. Kerstin Stangier, shares our perspective on how sustainability can be integrated into oligonucleotide manufacturing without compromising the high quality standards required for pharmaceutical production.
For BioSpring, sustainability is not limited to a single initiative. It means considering environmental and resource-related aspects across our operations and value chain. This includes resource-efficient process development, responsible energy management, the careful selection and use of raw materials, and responsible sourcing practices.
At the same time, resilient and reliable supply chains are becoming increasingly important. Strengthening supply chain transparency, assessing relevant risks and working closely with suppliers can contribute both to sustainability goals and to the long-term security of pharmaceutical manufacturing.
Our approach is therefore focused on making thoughtful and responsible choices throughout the value chain while continuing to meet the highest standards for quality, reliability and scalability in oligonucleotide manufacturing.
The article in Chemistry Today – Chimica Oggi provides further insights into BioSpring’s approach and the opportunities to embed sustainability considerations into the development and manufacture of therapeutic oligonucleotides.
Read the full article here: https://lnkd.in/eCGASa-b